Compare Msci Inc (MSCI) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Nuvalent Inc — how do they compare? Msci Inc trades at $562.98 (market cap $45.51B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Msci Inc is far larger — about 4.6× Nuvalent Inc's market cap, and Msci Inc pays a 1.31% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MSCI | NUVL | |
|---|---|---|
Market Cap | $45.51B | $9.81B |
Sector | Financials | Technology |
52-Week High | $643.83 | $123.96 |
52-Week Low | $511.84 | $72.16 |
Enterprise Value | $51.67B | $8.52B |
Dividend Yield | 1.31% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
